RECURRENT CHOLANGIOCARCINOMA
Clinical trials for RECURRENT CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo enters early trial for Tough-to-Treat digestive cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, guadecitabine and durvalumab, in people with advanced cancers of the liver, pancreas, bile duct, or gallbladder that have spread. The main goals are to find the safest dose and see what side effects occur. Researchers …
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for Tough-to-Treat cancers: drug trial targets specific genetic flaw
Disease control OngoingThis study is testing whether the drug olaparib can help control advanced cancers that have a specific genetic change (IDH1 or IDH2 mutation) and have stopped responding to standard treatments. It is enrolling adults with certain brain tumors, bile duct cancer, or other solid tum…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New 'Smart Bomb' drug trial offers hope for Tough-to-Treat bile duct cancer
Disease control OngoingThis study is testing a drug called sacituzumab govitecan in people with advanced bile duct cancer (cholangiocarcinoma) that has come back or spread after at least one prior treatment. The drug is designed to target cancer cells specifically, delivering a toxic agent directly to …
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC